Habano et al(52) demonstrated that PXR promoter methylation was involved in the regulation of intestinal PXR and CYP3A4 mRNA expression, which may be associated with the inter-individual variability in the drug responses of colon cancer cells. Here, NR1I2 is linked to malignant colon neoplasm.